Global Exhaled Nitric Oxide Detectors Market Size By Type (Fixed, Portable), By Application (Hospital, Research Institute), By Region, And Segment Forecasts, 2023 to 2032

The Global Exhaled Nitric Oxide Detectors Market was valued at USD 0.45 billion in 2023 and is projected to surpass USD 0.92 billion by 2031, growing at a CAGR of 9.3% during the forecast period (2023–2031). This growth is attributed to the increasing prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD), combined with the growing need for non-invasive and real-time monitoring tools in clinical and homecare settings. Exhaled nitric oxide (FeNO) detectors are essential diagnostic tools that assist in monitoring airway inflammation and personalizing treatment plans, particularly in asthma management.

Drivers

1. Rising Prevalence of Asthma and COPD:

Globally, respiratory disorders are on the rise due to urbanization, pollution, and lifestyle changes. Exhaled nitric oxide detectors enable early diagnosis and ongoing management of asthma, making them increasingly indispensable in both clinical and at-home healthcare setups.

2. Growing Emphasis on Non-Invasive Diagnostics:

Healthcare is shifting toward non-invasive solutions for diagnostics. FeNO detectors offer a quick, painless, and highly specific method to assess airway inflammation, improving patient compliance and long-term disease monitoring.

3. Technological Advancements in Portable Medical Devices:

Advancements in sensor miniaturization, digital integration, and Bluetooth connectivity are fueling the adoption of compact, user-friendly exhaled nitric oxide detectors, especially for remote monitoring and telemedicine applications.

Restraints

1. High Cost of Advanced Devices:

Despite their clinical value, the high initial cost of FeNO detectors, particularly for home use, can hinder adoption, especially in lower-income regions and among smaller healthcare providers.

2. Limited Reimbursement Policies:

In several countries, limited insurance coverage or unclear reimbursement structures for FeNO testing pose challenges to widespread clinical deployment.

Opportunity

1. Integration with Telehealth Platforms:

With the global push for remote patient management, integrating FeNO detectors into telehealth ecosystems represents a major growth opportunity, particularly for chronic asthma patients requiring frequent monitoring.

2. Untapped Emerging Markets:

Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing improvements in healthcare infrastructure and respiratory health awareness, creating opportunities for market expansion.

Market by System Type Insights

Based on system type, the Handheld Exhaled Nitric Oxide Detectors segment dominated the market in 2023, owing to their portability, ease of use, and integration with mobile health applications. These devices are increasingly favored by both clinicians and patients for in-clinic and remote usage. Meanwhile, Stationary Detectors retain importance in hospital environments where high throughput and comprehensive diagnostics are required.

Market by End-Use Insights

The Hospitals & Clinics segment led the market in 2023, accounting for the largest revenue share due to the high demand for accurate diagnostic tools in acute care settings. However, the Homecare Settings segment is expected to witness the highest growth rate, driven by the increasing trend of chronic disease management at home and the growing availability of user-friendly portable detectors.

Market by Regional Insights

North America held the largest share of the global exhaled nitric oxide detectors market in 2023, supported by advanced healthcare systems, high prevalence of asthma, and favorable reimbursement policies. Asia-Pacific is projected to be the fastest-growing region due to rising healthcare expenditure, urban pollution, and increased diagnosis of respiratory illnesses in countries like China and India.

Competitive Scenario

Key players in the Global Exhaled Nitric Oxide Detectors Market include Circassia Group Plc, Spirosure Inc., Bedfont Scientific Ltd., Philips Healthcare, and NIOX (formerly Aerocrine AB). These companies focus on product innovation, mobile integration, and strategic partnerships to expand market presence.

Key Developments:

In 2023, Circassia launched an AI-enabled update for its NIOX VERO device to enhance predictive accuracy in asthma control.

Spirosure announced a partnership in 2024 with telehealth providers to distribute its Fenom Pro® device directly to patients.

Bedfont Scientific expanded into new markets in Latin America in 2025, strengthening its global distribution network.

Scope of Work – Global Exhaled Nitric Oxide Detectors Market

Report Metric Details

Market Size (2023) USD 0.45 Billion

Projected Market Size (2031) USD 0.92 Billion

CAGR (2023–2031) 9.3%

Market Segments By System Type (Handheld, Stationary), End-use, Region

Growth Drivers Rising asthma cases, demand for non-invasive diagnostics

Opportunities Telehealth integration, Emerging markets expansion

FAQs

What is the current market size of the Global Exhaled Nitric Oxide Detectors Market?

The market wa